Intradiscal administration of autologous platelet-rich plasma in patients with Modic type 1 associated low back pain: A prospective pilot study.
Soya KawabataSota NagaiKei ItoHiroki TakedaDaiki IkedaYusuke KawanoShinjiro KanekoYukako ShiraishiYuichiro SanoYoshiharu OhnoNobuyuki FujitaPublished in: JOR spine (2024)
The safety and efficacy of PRP administration to the IVDs of patients with MC1 experiencing LBP were identified. Post-treatment MRI suggested improvement in inflammation, speculating that PRP suppressed inflammation and consequently relieved the patient's symptoms. Despite the small number of patients, this treatment is promising for patients with MC1 experiencing LBP. The study protocol has been reviewed and approved by the Certified Committee for Regenerative Medicine and the Japanese Ministry of Health, Labor and Welfare (Japan Registry of Clinical Trials [jRCT] No. jRCTb042210159).
Keyphrases
- platelet rich plasma
- clinical trial
- oxidative stress
- study protocol
- end stage renal disease
- randomized controlled trial
- healthcare
- public health
- ejection fraction
- newly diagnosed
- chronic kidney disease
- mental health
- stem cells
- computed tomography
- risk assessment
- peritoneal dialysis
- combination therapy
- health information
- phase ii
- patient reported
- placebo controlled